Clarivate

OCTOBER 25, 2023

Unlike in Part D, Part B drugs are physician administered and there is less certainty regarding which drugs will be tapped for negotiations (i.e., exclusions exist for orphan drug designation and biosimilar competition ). Nonetheless, Clarivate expects the initial list to include oncology treatments KEYTRUDA® and OPDIVO®.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

MAY 24, 2023

With 11 gene therapies already approved payers are bracing for impact as Cortellis Competitive Intelligence data identifies another 30 in late-stage pipelines. However, because this is a genetic condition and there’s a definitive diagnosis, hopefully that means the process will be relatively straightforward for patients and physicians.”

Patients 52

Patients Food and Drug Administration Biopharma FDA 52

Clarivate

DECEMBER 6, 2022

In a fiercely competitive U.S. While marquee IDNs attract national headlines, these smaller systems reflect how markets are adjusting to an increasingly value-based and competitive landscape. ChristianaCare’s future expansion plans could escalate the competition between Highmark and UPMC. ChristianaCare, Wilmington, Delaware.

Networking 52

Networking Healthcare Healthcare Competition 52

Clarivate

OCTOBER 7, 2021

Competition is imminent as the CheckMate-76K trial evaluating Bristol-Myers Squibb’s Opdivo in stage IIB-C melanoma patients is also poised to enter this setting. Kisqali plus letrozole demonstrated a significant OS benefit, but is that enough to displace physician favorite Ibrance? Kisqali in the battle of the CDK4/6 inhibitors 3.

Patients 91

Patients Safety Marketing Physicians 91

The Marketing Advantage

JULY 10, 2023

July 10, 2023 One of the functions most critical to maximizing the productivity and efficiency of the sales force’s efforts is call planning —how often a physician target should be seen by a sales representative. In fact, in one case, the prescriber was the spouse of a competitive sales representative.

Sales 40

Sales Consulting Specialization Prospecting 40

Clarivate

OCTOBER 10, 2022

Fruquintinib will face fierce competition should it be approved in the third- and later-line setting. The question of which KRAS inhibitor is most effective remains elusive, although being first to market in addition to strong efficacy and safety data could differentiate the more competitive agent. Key ESMO findings. months vs. 20.3

Marketing 52

Marketing Safety Patients Competition 52

Clarivate

DECEMBER 1, 2021

Treatment cost and compliance are key factors in sustaining effective long-term disease management, a powerful new oral option could be more widely accepted than the injectable competition and rapidly gain traction in the market, especially among primary care physicians.

Patients 52

Patients Safety Management Marketing 52

Clarivate

AUGUST 20, 2024

In 2026, CMS will select up to 15 additional Part B or Part D drugs for negotiations that take effect in 2028, and up to 20 additional drugs every year thereafter (Part B covers physician-administered drugs, including infusions of complex biologics). In highly competitive categories like diabetes, net price could be half of the list price.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

Clarivate

DECEMBER 14, 2023

IDNs coalesce along Competitive Service Regions As nonprofit IDNs push out from their home markets and for-profit and Catholic IDNs pull back from earlier expansions, distinct competitive service regions with common rivalries are developing across the nation.

Marketing 52

Marketing Healthcare Healthcare Insurance 52

Clarivate

OCTOBER 17, 2024

The Inflation Reduction Act instead allows the Centers for Medicare & Medicaid Services to begin negotiating Fair Maximum Prices for a growing list of Part D (outpatient) and Part B (physician-administered) drugs that represent the greatest cost to the federal government.

Healthcare 52

Healthcare Healthcare Government Insurance 52